MAPs, EAPs, and patient access: Suzanne Aitken on the challe...

Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of managed access programmes in the current pharmaceutical landscape.

Biotech ≠ tech: Why venture capital needs a new playbook for...

Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1

Capital efficient trials in a time of economic uncertainty

In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, pharma and biotech companies should address not just whether a trial

Pharma go-to-market transformation: Why cross-functional sil...

Pharmaceutical go-to-market transformation has become the industry's most urgent priority, yet cross-functional coordination remains pharma's biggest challenge.

Global unity in the face of uncertainty, with Paul Romness a...

NICE’s health inequalities modular update: Commentary on NIC...

NICE’s modular update on health inequalities, consulted on in January and finalised in May, has now been incorporated into its manual.1  A total of 26 individuals and organi